A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

This study is testing a three-drug combination — paclitaxel (chemotherapy), apatinib (a drug that cuts off blood supply to tumors), and adebrelimab (an immunotherapy) — for people with stomach or gastroesophageal junction cancer that has already been treated with immunotherapy but has stopped responding. **You may be eligible if...** - You are 18–75 years old - You have advanced or metastatic stomach or gastroesophageal junction cancer confirmed by biopsy - Your cancer progressed on or you couldn't tolerate prior immunotherapy (PD-1/PD-L1 treatment) - You have had no more than 2 prior lines of treatment - You have at least one measurable tumor on scans - Your general health is good (ECOG 0 or 1) - Your blood, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - You have not previously received immunotherapy - You have had more than 2 prior lines of treatment - Your organ function (heart, liver, kidneys) does not meet the required levels Talk to your doctor to see if this trial is right for you.